ONTY News Alert Oncothyreon Inc (ONTY) 1.89 12/25/2014 07:06

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oncothyreon Inc (ONTY) 1.89 $ONTY

Oncothyreon (ONTY) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 7:42AM CST
Oncothyreon is one stock that might be an intriguing choice for investors as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 58
ONTY: 1.89 (+0.01)

Biotech Weekly: Top Ideas From The San Antonio Breast Cancer Symposium
Daniel Ward - Seeking Alpha - Tue Dec 16, 10:00AM CST
Approaching 7,500 scientists, advocates, professors, and healthcare professional descended upon the San Antonio Riverwalk to present and discuss groundbreaking research in the field of breast cancer at the San Antonio Breast Cancer Symposium (SABCS)...
ONTY: 1.89 (+0.01), CELGZ: 3.34 (-0.01), CELG: 109.60 (+3.48)

Oncothyreon Up on Gaining License to Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 5:05PM CST
Shares of Oncothyreon Inc. (ONTY) soared 18.1% after it announced an exclusive license agreement with Array.
ONTY: 1.89 (+0.01)

Hot Stock: Oncothyreon, Shares Drop 8.8% (ONTY)
Comtex SmarTrend(R) - Mon Dec 15, 10:36AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's worst performing low-priced stocks, down 8.8% to $1.86 on 2.4x average daily volume. Oncothyreon has traded 1.2 million shares thus far today, vs. average volume of 511,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's -0.7%) and underperformed the S&P 500 (-8.8% to the S&P's -0.6%) during today's trading.
ONTY: 1.89 (+0.01)

Hot Stock: Oncothyreon, Shares Gain 5.3% (ONTY)
Comtex SmarTrend(R) - Fri Dec 12, 10:06AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 5.3% to $1.80 on 2.8x average daily volume. Oncothyreon has traded 1.4 million shares thus far today, vs. average volume of 508,000 shares per day. The stock has outperformed the Dow (5.3% to the Dow's -1.0%) and outperformed the S&P 500 (5.3% to the S&P's -0.9%) during today's trading.
ONTY: 1.89 (+0.01)

Oncothyreon secures exclusive license to HER2 inhibitor
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 9:50AM CST

ONTY: 1.89 (+0.01), ARRY: 4.64 (+0.07)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 8:16AM CST

FRO: 2.43 (-0.01), GDP: 4.93 (-0.22), TLM: 7.84 (unch), ONVO: 6.84 (+0.03), EOX: 1.33 (+0.05), CCXI: 6.64 (-0.04), HCCI: 11.76 (-0.41), ONTY: 1.89 (+0.01), ADBE: 74.74 (+0.36)

Oncothyreon Announces Presentation of Positive ONT-380 Data at San Antonio Breast Cancer Symposium
GlobeNewswire - Fri Dec 12, 6:11AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that positive preliminary data from two ongoing Phase 1b trials of ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor, will be presented at the San Antonio Breast Cancer Symposium.
ONTY: 1.89 (+0.01)

Oncothyreon Announces Exclusive License Agreement With Array BioPharma for ONT-380
GlobeNewswire - Fri Dec 12, 6:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that Array BioPharma Inc. (Nasdaq:ARRY) has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor. The license agreement replaces the prior Development and Collaboration Agreement under which Oncothyreon and Array were jointly developing ONT-380.
ONTY: 1.89 (+0.01), ARRY: 4.64 (+0.07)

Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST

HTBX: 4.18 (-0.22), BIB: 122.51 (+3.83), INCY: 71.57 (+1.99), PFE: 31.42 (-0.03), IBB: 299.80 (+5.12), DRGS: 53.60 (unch), BIND: 5.73 (+0.06), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), ONTY: 1.89 (+0.01), ECYT: 6.33 (+0.24), BIS: 47.26 (-1.74), CLVS: 54.58 (+0.43), AZN: 70.44 (+0.26), MRK: 57.46 (+0.25), ARIA: 6.81 (+0.15), IRY: 47.28 (-0.01), IXJ: 100.54 (+0.55), FPRX: 26.12 (+0.07)

Oncothyreon Inc. (ONTY) in Focus: Stock Surges 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 7:44AM CST
Oncothyreon Inc. (ONTY) was a big mover last session, as the company saw its shares rise slightly over 10% on the day
BIIB: 340.89 (+5.13), ILMN: 186.22 (+2.72), AMAG: 43.02 (+0.90), ONTY: 1.89 (+0.01)

Oncothyreon Up 8.9%, Shares Break Through Resistance (ONTY)
Comtex SmarTrend(R) - Wed Nov 26, 11:35AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 8.9% to $1.84 on 1.8x average daily volume. Thus far today, Oncothyreon has traded 817,000 shares, vs. average volume of 460,000 shares per day. The stock has outperformed the Dow (8.9% to the Dow's -0.1%) and outperformed the S&P 500 (8.9% to the S&P's 0.1%) during today's trading.
ONTY: 1.89 (+0.01)

Oncothyreon to Present at Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 7:01AM CST
Oncothyreon Inc. (Nasdaq:ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Stifel 2014 Healthcare Conference in New York on Wednesday, Nov. 19, 2014 at 3:00 p.m. Eastern.
ONTY: 1.89 (+0.01)

Oncothyreon and Celldex Therapeutics Announce Initiation of Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab
GlobeNewswire - Mon Nov 10, 3:10PM CST
Oncothyreon Inc. (Nasdaq:ONTY) and Celldex Therapeutics, Inc., (Nasdaq:CLDX) today announced that they have initiated a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes.
CLDX: 17.08 (-0.18), ONTY: 1.89 (+0.01)

Oncothyreon's (ONTY) CEO Robert Kirkman on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:04PM CST

ONTY: 1.89 (+0.01)

Oncothyreon posts 3Q loss
Automated Insights - Thu Nov 06, 5:42PM CST
SEATTLE (AP) _ Oncothyreon Inc. (ONTY) on Thursday reported a loss of $6.7 million in its third quarter.
ONTY: 1.89 (+0.01)

Oncothyreon beats by $0.02
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:49PM CST

ONTY: 1.89 (+0.01)

Oncothyreon Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 3:01PM CST
Oncothyreon Inc. (Nasdaq:ONTY) today reported financial results for the third quarter ended September 30, 2014.
ONTY: 1.89 (+0.01), ARRY: 4.64 (+0.07)

Oncothyreon Announces Third Quarter 2014 Financial Results Conference Call
GlobeNewswire - Thu Oct 30, 7:00AM CDT
Oncothyreon Inc. (Nasdaq:ONTY) today announced that it will conduct a conference call on Thursday, November 6, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its third quarter 2014 financial results and provide a corporate update and review of its pipeline of products in development.
ONTY: 1.89 (+0.01)

Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 15.29 (+0.15), BCRX: 11.83 (+0.76), NBIX: 21.33 (+0.09), ONTY: 1.89 (+0.01), DYAX: 14.13 (+0.30)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 107

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 138

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 53

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 70

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Microinsurance Market Expected to Surpass $11 Billion by 2034

Updated Category News Views 137

Growth Trajectory of the Global Microinsurance Market The microinsurance market is witnessing remarkable transformation as consumer demands shift towards financial inclusion, coupled with increasing awareness of the myriad advantages insurance provides. This positive trend is fueled by government initiatives aimed at regulation and expansion of microinsurance offerings,...

Continue Reading
Ormat Technologies Launches Secondary Stock Offering

Updated Category News Views 188

Ormat Technologies Launches Secondary Stock Offering Ormat Technologies, Inc. (NYSE: ORA), renowned for its innovative geothermal and renewable energy solutions, recently announced an exciting development in the investment realm—the initiation of an underwritten secondary offering. This offering encompasses a total of 3,700,000 shares of common stock on behalf of ORIX...

Continue Reading
MongoDB Executive Share Transactions Highlight Growth Potential

Updated Category News Views 132

Insights from MongoDB Executive Share Transactions Cochran Hope F, a director at MongoDB, Inc. (NASDAQ: MDB), recently made notable moves with the company's Class A Common Stock, and these transactions were disclosed in the latest SEC filings. This activity has attracted attention from investors. In September, the director sold 1,174 shares at $224.38 each, which brought...

Continue Reading
Essential Guidance for Navigating Hurricane Travel Risks

Updated Category News Views 69

Essential Guidance for Navigating Hurricane Travel Risks Hurricane season brings with it the potential for severe weather that can disrupt travel plans and lead to significant financial losses. As storms like Hurricane Helene have shown, the impact can be widespread, devastating homes and infrastructure, particularly in the southeastern regions. During these turbulent...

Continue Reading
Ascend Performance Materials Launches High-Purity Production

Updated Category News Views 279

Ascend Performance Materials Starts High-Purity Acrylonitrile Production Ascend Performance Materials has recently announced an exciting new phase in its production capabilities. The company is now producing high-purity acrylonitrile at its Chocolate Bayou facility. This advancement comes after the successful installation and commissioning of state-of-the-art purification...

Continue Reading